[Vasoactive intestinal peptide (VIP)-induced pulmonary vasodilation mediated by EDRF/NO in isolated perfused rat lungs].
We studied the effects of Vasoactive Intestinal Peptide (VIP) on the pulmonary circulation in isolated perfused rat lungs. VIP caused pulmonary vasodilation in a dose-dependent manner. This effect was inhibited by pretreatment with L-N omega-nitro-arginine (L-NNA), a competitive inhibitor of endothelium-derived relaxing factor (EDRF/NO), but not by meclofenamate, a cyclooxygenase inhibitor. Addition of L-arginine, a substrate of EDRF/NO, after treatment with L-NNA reversed VIP-induced pulmonary vasodilation. These results indicate that VIP causes pulmonary vasodilation, and they suggest a role for EDRF/NO in VIP-induced pulmonary vasodilation in isolated rat lungs.
Iwabuchi
S
S
Department of Thoracic Surgery, Tohoku University, Sendai, Japan.
Ono
S
S
Funata
J
J
Hoshikawa
Y
Y
Ueda
S
S
Ashino
Y
Y
Tanita
T
T
Fujimura
S
S
Koike
K
K
D000818:Animals; D066298:In Vitro Techniques; D009569:Nitric Oxide / Q000502:physiology*; D011652:Pulmonary Circulation / Q000187:drug effects*; D051381:Rats; D011915:Rats, Inbred BUF; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*; D014664:Vasodilation / Q000187:drug effects*
D009569:Nitric Oxide; D014660:Vasoactive Intestinal Peptide